Dow Down1.29% Nasdaq Down3.25%

CTI BioPharma Corp. (CTIC)

-NasdaqCM
1.12 Down 0.02(1.75%) Feb 5, 4:00PM EST
ProfileGet Profile for:
CTI BioPharma Corp.
3101 Western Avenue
Suite 600
Seattle, WA 98121
United States - Map
Phone: 206-282-7100
Fax: 206-284-6206
Website: http://www.ctibiopharma.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Biotechnology
Full Time Employees:132

Business Summary 

CTI BioPharma Corp., a biopharmaceutical company, engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It primarily focuses on the commercialization of PIXUVRI, an aza-anthracenedione derivative for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma in the European Union. The company is also developing Pacritinib, an oral multikinase inhibitor with activity against Janus Kinase 2 and FMS-like tyrosine kinase, which is in Phase III clinical trials for the treatment of myelofibrosis. In addition, it is developing Tosedostat, an oral once-daily aminopeptidase inhibitor that is in Phase II/III clinical trials for the treatment of acute myeloid leukemia; and Opaxio, a chemotherapeutic agent, which is in Phase III clinical trials for the treatment of various solid tumors, including non-small cell lung, ovarian, breast, and prostate cancers. The company has development, commercialization, and license agreement with Baxter International Inc., Baxter Healthcare Corporation, and Baxter Healthcare SA for the development and commercialization of pacritinib for use in oncology and other therapeutic areas. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on CTI BioPharma Corp.

Corporate Governance 
CTI BioPharma Corp.’s ISS Governance QuickScore as of Feb 1, 2016 is 10. The pillar scores are Audit: 5; Board: 8; Shareholder Rights: 9; Compensation: 10.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
 PayExercised
Dr. James A. Bianco M.D., 59
Chief Exec. Officer, Pres, Principal Founder, Exec. Director and Member of Exec. Committee
1.74M0.00
Dr. Jack W. Singer M.D., 73
Co-Founder, Interim Chief Medical Officer, Exec. VP, Global Head of Translational Medicine, Chief Scientific Officer and Exec. Director
600.00K0.00
Mr. Louis A. Bianco CPA, 63
Co-Founder, Chief Governance Officer, Exec. VP of Fin. & Admin. and Sec.
636.00K0.00
Dr. Matthew James Plunkett Ph.D., 44
Chief Bus. Officer and Exec. VP
552.00K0.00
Ms. Monique M. Greer Sr., 57
Sr. VP of Corp. Communications and Investor Relations
N/AN/A
Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders